Aileron Therapeutics Inc (NASDAQ:ALRN) major shareholder Apple Tree Partners Ii Lp sold 150,000 shares of the company’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $9.80, for a total transaction of $1,470,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Shares of Aileron Therapeutics Inc (NASDAQ:ALRN) opened at $9.69 on Friday. Aileron Therapeutics Inc has a 12 month low of $8.77 and a 12 month high of $15.48.
Separately, Zacks Investment Research raised shares of Aileron Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $19.33.
A number of hedge funds and other institutional investors have recently modified their holdings of ALRN. California State Teachers Retirement System acquired a new stake in Aileron Therapeutics in the 3rd quarter valued at about $110,000. Vanguard Group Inc. acquired a new stake in Aileron Therapeutics in the 2nd quarter valued at about $111,000. Tudor Investment Corp ET AL acquired a new stake in Aileron Therapeutics in the 2nd quarter valued at about $112,000. Bank of New York Mellon Corp acquired a new stake in Aileron Therapeutics in the 3rd quarter valued at about $135,000. Finally, Citadel Advisors LLC acquired a new stake in Aileron Therapeutics in the 2nd quarter valued at about $141,000. 7.64% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This news story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/01/14/insider-selling-aileron-therapeutics-inc-alrn-major-shareholder-sells-1470000-00-in-stock.html.
About Aileron Therapeutics
Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.